Advances in Liquid Biopsy Technologies

Up until now, Big Data in healthcare has failed to drive any real progress in curing disease. However, we have just now reached a cost and throughput threshold in sequencing and bioinformatic technology that is enabling the collection and analysis of whole exome and transcriptome data from blood, not just in oncology, but in diseases where no molecular data has been available before. This vast amount of data offers opportunities for discovery. Collected over time across hundreds of thousands of patients, this data is finally unlocking a true molecular classification of disease that will drive vast innovation in treatments and cures.

Learning Objectives:

1. Explain why Big Data in healthcare has not led to any revolutionary clinical discoveries.

2. Discuss how the serial collection of exome and transcriptome data from blood empower new possibilities in understanding disease.

3. Discuss how AI applied to this data make discoveries that were not possible before.